# Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease

> **NCT06984484** · NA · RECRUITING · sponsor: **Devintec Sagl** · enrollment: 208 (estimated)

## Conditions studied

- Gastroesophageal Reflux Disease (GERD)

## Interventions

- **DEVICE:** Afluxin®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06984484
- **Lead sponsor:** Devintec Sagl
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-02
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06984484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06984484, "Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06984484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*